HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hausen, B. Articles by Borst, H. G. Search for Related Content PubMed PubMed Citation Articles by Hausen, B. Articles by Borst, H. G.

The Annals of Thoracic Surgery, Vol 58, 999-1004, Copyright © 1994 by The Society of Thoracic Surgeons

ARTICLES

Low-dose cyclosporine therapy in triple-drug immunosuppression for heart transplant recipients

B Hausen, S Demertzis, R Rohde, JM Albes, HJ Schafers and HG Borst
Division of Thoracic and Cardiovascular Surgery, Surgical Center, Hannover Medical School, Germany.

The toxicity of long-term immunosuppressive therapy has become a major concern in long-term follow-up of heart transplant recipients. In this respect the quality of renal function is undoubtedly linked to cyclosporin A (CsA) drug levels. In cardiac transplantation, specific CsA trough levels have historically been maintained between 250 and 350 micrograms/L in many centers without direct evidence for the necessity of such high levels while using triple-drug immunosuppression. This retrospective analysis compares the incidence of acute and chronic graft rejection as well as overall mortality between groups of patients with high (250 to 350 micrograms/L) and low (150 to 250 micrograms/L) specific CsA trough levels. A total of 332 patients who underwent heart transplantation between October 1985 and October 1992 with a minimum follow-up of 30 days were included in this study (46 women and 276 men; aged, 44 +/- 12 years; mean follow-up, 1,122 +/- 777 days). Standard triple-drug immunosuppression included first-year specific CsA target trough levels of 250 to 300 micrograms/L. Patients were grouped according to their average creatinine level in the first postoperative year (group I, < 130 mumol/L, n = 234; group II, > or = 130 mumol/L, n = 98). The overall 5-year survival excluding the early 30-day mortality was 92% (group I, 216/232) and 91% (group II, 89/98) with 75% of the mortality due to chronic rejection. The rate of rejection for the entire follow-up period was similar in both groups (first year: group I, 3.2 +/- 2.6 rejection/patient/year; group II, 3.6 +/- 2.7 rejection/patient/year; p = not significant).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				L. U. Nwakanma, A. S. Shah, J. V. Conte, and W. A. Baumgartner Heart Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1539 - 1578. [Full Text]

				X. M. Mueller Drug immunosuppression therapy for adult heart transplantation. Part 2: clinical applications and results Ann. Thorac. Surg., January 1, 2004; 77(1): 363 - 371. [Abstract] [Full Text] [PDF]

				B. T. Bethea, D. D. Yuh, J. V. Conte, and W. A. Baumgartner Heart Transplantation Card. Surg. Adult, January 1, 2003; 2(2003): 1427 - 1460. [Full Text]

				S Fraund, K Pethig, U Franke, T Wahlers, W Harringer, J Cremer, H-G Fieguth, P Oppelt, and A Haverich Ten year survival after heart transplantation: palliative procedure or successful long term treatment? Heart, July 1, 1999; 82(1): 47 - 51. [Abstract] [Full Text] [PDF]

				A. H. WILKINSON and D. J. COHEN Renal Failure in the Recipients of Nonrenal Solid Organ Transplants J. Am. Soc. Nephrol., May 1, 1999; 10(5): 1136 - 1144. [Full Text]

				H. P. B.-L. Rocca, G. Sutsch, J. Schneider, F. Follath, and W. Kiowski Natural Course of Moderate Cardiac Allograft Rejection (International Society for Heart Transplantation Grade 2) Early and Late After Transplantation Circulation, September 15, 1996; 94(6): 1334 - 1338. [Abstract] [Full Text]